Lexicon Pharma (LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel...

|About: Lexicon Pharmaceuticals, Inc. (LXRX)|By:, SA News Editor

Lexicon Pharma (LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel syndrome receives fast track status from the FDA.